Clinical Trial Update: A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 study evaluating discontinuation of nucleos(t)ide analog therapy in e-antigen negative chronic hepatitis B participants has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Nucleos(t)ide analog therapy (nucleos(t)ide analog)

Snippet

Sponsor: Janssen Pharmaceutica N.V., Belgium | Conditions: Hepatitis B, Chronic | EARLY_Phase 1 | Status: WITHDRAWN